
Souheil El-Chemaly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8583846/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Airway complications in lung transplant recipients with telomereâ€related interstitial lung disease. Clinical Transplantation, 2022, 36, e14552.	1.6	6
2	Interstitial lung abnormalities are associated with decreased mean telomere length. European Respiratory Journal, 2022, 60, 2101814.	6.7	8
3	ETV2 regulates PARP-1 binding protein to induce ER stress–mediated death in tuberin-deficient cells. Life Science Alliance, 2022, 5, e202201369.	2.8	2
4	Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens. Frontiers in Medicine, 2021, 8, 607720.	2.6	13
5	Editorial: Advances and Updates in Diffuse Cystic Lung Diseases. Frontiers in Medicine, 2021, 8, 691688.	2.6	1
6	Intratracheal transplantation of trophoblast stem cells attenuates acute lung injury in mice. Stem Cell Research and Therapy, 2021, 12, 487.	5.5	1
7	CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 312-325.	5.6	24
8	Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells. Proceedings of the United States of America, 2021, 118, .	7.1	13
9	Blocking hyaluronan synthesis alleviates acute lung allograft rejection. JCI Insight, 2021, 6, .	5.0	4
10	The lung microbiome in end-stage Lymphangioleiomyomatosis. Respiratory Research, 2021, 22, 277.	3.6	0
11	Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival. ERJ Open Research, 2020, 6, 00003-2020.	2.6	33
12	FK506 induces lung lymphatic endothelial cell senescence and downregulates LYVE-1 expression, with associated decreased hyaluronan uptake. Molecular Medicine, 2020, 26, 75.	4.4	4
13	Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case–Control Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1710-1713.	5.6	108
14	Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. European Respiratory Journal, 2020, 55, 1902370.	6.7	7
15	Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres. Frontiers in Immunology, 2020, 11, 1063.	4.8	6
16	Lung transplant in familial pulmonary fibrosis: the road ahead. Jornal Brasileiro De Pneumologia, 2020, 46, e20200487-e20200487.	0.7	2
17	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. Scientific Reports, 2019, 9, 14802.	3.3	12
18	Palmitic Acid–Rich High-Fat Diet Exacerbates Experimental Pulmonary Fibrosis by Modulating Endoplasmic Reticulum Stress. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 737-746.	2.9	73

SOUHEIL EL-CHEMALY

#	Article	IF	CITATIONS
19	Hyaluronan and LYVE-1 and allograft function in lung transplantation recipients. Scientific Reports, 2019, 9, 9003.	3.3	6
20	Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies. Annals of the American Thoracic Society, 2019, 16, 1131-1137.	3.2	22
21	Glycogen synthase kinase 3-β inhibition induces lymphangiogenesis through β-catenin-dependent and mTOR-independent pathways. PLoS ONE, 2019, 14, e0213831.	2.5	9
22	Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis. Orphanet Journal of Rare Diseases, 2019, 14, 72.	2.7	5
23	Generalised mosaicism for TSC2 mutation in isolated lymphangioleiomyomatosis. European Respiratory Journal, 2019, 54, 1900938.	6.7	5
24	Telomeres in Interstitial Lung Disease: The Short and the Long of It. Annals of the American Thoracic Society, 2019, 16, 175-181.	3.2	55
25	In-hospital and subsequent mortality among lung transplant recipients with a prolonged initial hospitalization. American Journal of Transplantation, 2019, 19, 532-539.	4.7	4
26	An Ethical Framework for the Care of Patients with Prolonged Hospitalization Following Lung Transplantation. HEC Forum, 2019, 31, 49-62.	0.8	5
27	Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction. Journal of Heart and Lung Transplantation, 2018, 37, 340-348.	0.6	30
28	Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast Activation by Regulating PI3K/Akt/ROCK Pathway via CD148. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 208-215.	2.9	56
29	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 94-104.	0.8	66
30	Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients. Annals of Thoracic Surgery, 2018, 105, 441-447.	1.3	12
31	The impact of screening method on HLA antibody detection before and after lung transplantation: A prospective pilot study. Journal of Heart and Lung Transplantation, 2018, 37, 531-533.	0.6	4
32	Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. Chest, 2018, 154, 1070-1082.	0.8	13
33	[18F]Fluorocholine and [18F]Fluoroacetate PET as Imaging Biomarkers to Assess Phosphatidylcholine and Mitochondrial Metabolism in Preclinical Models of TSC and LAM. Clinical Cancer Research, 2018, 24, 5925-5938.	7.0	8
34	The Immunome in Two Inherited Forms of Pulmonary Fibrosis. Frontiers in Immunology, 2018, 9, 76.	4.8	19
35	Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. PLoS ONE, 2018, 13, e0194193.	2.5	29
36	Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 206-212.	0.2	3

SOUHEIL EL-CHEMALY

#	Article	IF	CITATIONS
37	The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis. European Respiratory Review, 2017, 26, 160004.	7.1	13
38	Survival and outcomes after lung transplantation for non-scleroderma connective tissue–related interstitial lung disease. Journal of Heart and Lung Transplantation, 2017, 36, 763-769.	0.6	55
39	Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Research, 2017, 77, 1492-1502.	0.9	17
40	Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis. Chest, 2017, 151, 1302-1310.	0.8	46
41	Lymphatic Changes in Respiratory Diseases: More than Just Remodeling of the Lung?. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 272-279.	2.9	41
42	Broadening the investigation—short telomeres and lung transplantation outcomes in pulmonary fibrosis. Journal of Heart and Lung Transplantation, 2017, 36, 833-834.	0.6	1
43	Lymphatic Vessels: The Next Frontier in Lung Transplant. Annals of the American Thoracic Society, 2017, 14, S226-S232.	3.2	26
44	The <i>MUC5B</i> promoter polymorphism is associated with specific interstitial lung abnormality subtypes. European Respiratory Journal, 2017, 50, 1700537.	6.7	55
45	Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop. JCI Insight, 2017, 2, .	5.0	55
46	Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. PLoS ONE, 2016, 11, e0162409.	2.5	30
47	Predictors and outcomes of unplanned early rehospitalization in the first year following lung transplantation. Clinical Transplantation, 2016, 30, 1053-1058.	1.6	8
48	Genetics and Idiopathic Interstitial Pneumonias. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 321-330.	2.1	5
49	Hermansky-Pudlak Syndrome. Clinics in Chest Medicine, 2016, 37, 505-511.	2.1	82
50	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA - Journal of the American Medical Association, 2016, 315, 672.	7.4	333
51	Donor-acquired fat embolism syndrome after lung transplantation. European Journal of Cardio-thoracic Surgery, 2016, 49, 1344-1347.	1.4	11
52	Short Telomeres, Telomeropathy, and Subclinical Extrapulmonary Organ Damage in Patients With Interstitial Lung Disease. Chest, 2015, 147, 1549-1557.	0.8	38
53	The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials. Expert Review of Respiratory Medicine, 2015, 9, 195-204.	2.5	6
54	Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection. Journal of Clinical Investigation, 2015, 125, 4255-4268.	8.2	79

#	Article	IF	CITATIONS
55	Transforming Growth Factor-β1 Downregulates Vascular Endothelial Growth Factor-D Expression in Human Lung Fibroblasts via the Jun NH2-Terminal Kinase Signaling Pathway. Molecular Medicine, 2014, 20, 120-134.	4.4	33
56	Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?. Expert Review of Respiratory Medicine, 2014, 8, 657-660.	2.5	20
57	Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. European Respiratory Review, 2014, 23, 30-35.	7.1	18
58	Glucose Transporter-1 Distribution in Fibrotic Lung Disease. Chest, 2013, 143, 1685-1691.	0.8	47
59	Natural History of Pulmonary Fibrosis in Two Subjects With the Same Telomerase Mutation. Chest, 2011, 139, 1203-1209.	0.8	47
60	Lymphatics in Idiopathic Pulmonary Fibrosis: New Insights into an Old Disease. Lymphatic Research and Biology, 2009, 7, 197-203.	1.1	26
61	Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3958-3963.	7.1	113
62	<i>Lymphatics in Lung Disease</i> . Annals of the New York Academy of Sciences, 2008, 1131, 195-202.	3.8	63